Google (NASDAQ:GOOG): based on what it sees as the increasing adoption of the company’s Enhanced Campaigns initiative, and strong growth in its display business, Cantor has raised its price target on the search engine giant from $900 to $1030 and maintained its Buy rating on the shares.
Lululemon Athletica (NASDAQ:LULU): Channel checks conducted by Canaccord have revealed that stores have begun re-stocking two of the three previously recalled yoga style pants. The firm sees the company as benefiting from pent up demand for the inventory, after they were pulled for a transparency problem. Increased traffic and substitute purchases will also help boost sales. Canaccord rates the shares at Buy, with a price target for $92, up from 487.
Biogen (NASDAQ:BIIB): In its eighth week of launch, scripts for Biogen’s multiple sclerosis drug Tecfidera were up 12 percent to 2,203, according to Citigroup. The firm notes that it took 54 weeks for Novartis’ (NYSE:NVS) Gilenya to reach that scrip level, and that Tecfidera is set to beat Q2 and 2013 estimates by a large amount. Citi keeps a Buy rating on the shares.
KeyCorp (NYSE:KEY): Oppenheimer sees KeyCorp’s multiple as having room to expand, and that sentiment towards the name continues to improve. The firm also expects the bank’s EPS to increase in 2014, and keeps an Outperform rating on the shares.
Investing Insights: Is Google A Buy At All-Time Highs?